1. Van Der Westhuizen E, Van Der Merwe E. The safety and ... filehospitalists can avoid. Journal of...

1. Van Der Westhuizen E, Van Der Merwe E. The safety and efficacy of low-dose oral contraceptives. SA Pharmaceutical Journal 2101;77:22-28. 2. Kakuda TN, Scholler-Gyure M, Hoetelmans RMW. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clinical Pharmacokinetics 2011;50:25-39. 3. Gregory KJ, Dong EN, Meiler J, Conn PJ. Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential. Neuropharmacology 2011;60:66-81. 4. Zalila H, Elloumi H, Gaha N, Ghachem R, Ghazali I, Boussetta A. Acute psychosis under efavirenz in a HIV patient. Tunisie Medicale 2010;88:106-108. 5. Wedi B. Definitions and mechanisms of drug hypersensitivity. Expert Review of Clinical Pharmacology 2010;3:539-551. 6. Trocha M, Merwid-Lad A, Ksiadzyna D, Szandruk M, Szelag A. Impact of malnutrition on drugs' action. Gastroenterologia Polska 2010;17:11-16. 7. Sullivan RJ, Pantanowitz L. New drug targets in Kaposi sarcoma. Expert Opinion on Therapeutic Targets 2010;14:1355-1366. 8. Suh HS, Choi S, Khattar P, Choi N, Lee SC. Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes. Journal of Neuroimmune Pharmacology 2010;5:521-532. 9. Singer EJ, Valdes-Sueiras M, Commins D, Levine A. Neurologic Presentations of AIDS. Neurologic Clinics 2010;28:253-275. 10. Serasli E, Michaelidis V, Kosmas A, Antoniadou M, Tsara V. Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension. Recent Patents on Cardiovascular Drug Discovery 2010;5:184-195. 11. Senousy BE, Belal SI, Draganov PV. Hepatotoxic effects of therapies for tuberculosis. Nature Reviews Gastroenterology and Hepatology 2010;7:543-556. 12. Schiedel M. Medicine: HIV-1 eradication by means of "shock & kill" strategy. [German]. Pharmazie in Unserer Zeit 2010;39:171-173. 13. Satterfield JM, Crabb R. Cognitive-Behavioral Therapy for Depression in an Older Gay Man: A Clinical Case Study. Cognitive and Behavioral Practice 2010;17:45-55. 14. Rubio R, Rodriguez V, Llenas J, Fiorante S, Matarranz M. Treatment of HIV infection. Antiretroviral drugs. [Spanish]. Medicine 2010;10:4048-4060. 15. Rakhmanina NY, Van Den Anker JN. Efavirenz in the therapy of HIV infection Rakhmanina & van den Anker Efavirenz. Expert Opinion on Drug Metabolism and Toxicology 2010;6:95-103. 16. Potschka H. Targeting regulation of ABC efflux transporters in brain diseases: A novel therapeutic approach. Pharmacology and Therapeutics 2010;125:118-127. 17. Perez M, de Vinuesa AG, Sanchez-Duffhues G, et al. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Current HIV Research 2010;8:418-429. 18. Paquet P, Pierard GE. New insights in toxic epidermal necrolysis (lyells syndrome): Clinical considerations, pathobiology and targeted treatments revisited. Drug Safety 2010;33:189-212. 19. Paige NM, Vazirani SS, Graber CJ. The top 10 infectious disease pitfalls that

hospitalists can avoid. Journal of Hospital Medicine 2010;5:42-45. 20. Ozer JS, Chetty R, Kenna G, et al. Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regulatory Toxicology and Pharmacology 2010;56:237-246. 21. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clinical Pharmacokinetics 2010;49:509-533. 22. Nitsche CJ, Jamieson N, Lerch MM, Mayerle JV. Drug induced pancreatitis. Best Practice and Research: Clinical Gastroenterology 2010;24:143-155. 23. Ngaimisi E, Mugusi S, Minzi OM, et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clinical Pharmacology and Therapeutics 2010;88:676-684. 24. Nelson AL. DMPA: Battered and bruised but still needed and used in the USA. Expert Review of Obstetrics and Gynecology 2010;5:673-686. 25. Musette P, Brandi ML, Cacoub P, Kaufman JM, Rizzoli R, Reginster JY. Treatment of osteoporosis: Recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporosis International 2010;21:723-732. 26. Morar N, Willis-Owen SA, Maurer T, Bunker CB. HIV-associated psoriasis: pathogenesis, clinical features, and management. The Lancet Infectious Diseases 2010;10:470-478. 27. Mkele G. The role of the pharmacist in TB management. SA Pharmaceutical Journal 2010;77:18-20. 28. Mischo M, Nigg C, Kiss A. Depression. [German]. Schweizerische Rundschau fur Medizin - Praxis 2010;99:271-277. 29. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends in Pharmacological Sciences 2010;31:246-254. 30. McKeage K, Scott LJ. Darunavir: In treatment-experienced pediatric patients with HIV-1 infection. Pediatric Drugs 2010;12:123-131. 31. Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: Mechanisms and clinical implications. American Journal of Medicine 2010;123:877-884. 32. Martinez E, Nelson M. Simplification of antiretroviral therapy with etravirine. AIDS Reviews 2010;12:52-59. 33. Marsden MD, Zack JA. Establishment and maintenance of HIV latency: Model systems and opportunities for intervention. Future Virology 2010;5:97-109. 34. Margolis DM. Mechanisms of HIV latency: An emerging picture of complexity. Current HIV/AIDS Reports 2010;7:37-43. 35. Mandava N, Oberoi RK, Minocha M, Mitra AK. Transporter targeted drug delivery. Journal of Drug Delivery Science and Technology 2010;20:89-99. 36. Mai A. Small-molecule chromatin-modifying agents: Therapeutic applications. Epigenomics 2010;2:307-324. 37. Loo TT, Ross CJD, Sistonen J, et al. Pharmacogenomics and active surveillance for serious adverse drug reactions in children. Pharmacogenomics 2010;11:1269-1285. 38. Lo J, Grinspoon SK. Adrenal function in HIV infection. Current Opinion in Endocrinology, Diabetes and Obesity 2010;17:205-209. 39. Liu Q, Kim DI, Syme J, Luvalle P, Burke B, Roux KJ. Dynamics of lamin-a processing following precursor accumulation. PLoS ONE 2010;5:1-10. 40. Lenz JCC, Rockstroh JK. Vicriviroc, a new CC-chemokine receptor 5 inhibitor for

treatment of HIV: Properties, promises and challenges. Expert Opinion on Drug Metabolism and Toxicology 2010;6:1139-1150. 41. Lee K, Vivithanaporn P, Siemieniuk RA, et al. Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS. BMC Neurology 2010;10. 42. Lalonde RG, Thomas R, Rachlis A, et al. Successful implementation of a national HLA-B*5701 genetic testing service in Canada. Tissue Antigens 2010;75:12-18. 43. Keedy KS, Margolis DM. Therapy for persistent HIV. Trends in Pharmacological Sciences 2010;31:206-211. 44. Kearney F, Moore AR, Donegan CF, Lambert J. The ageing of HIV: Implications for geriatric medicine. Age and Ageing 2010;39:536-541. 45. Kalia LV, Lee L, Kalia SK, et al. Thoracic myelopathy from coincident fluorosis and epidural lipomatosis. Canadian Journal of Neurological Sciences 2010;37:276-278. 46. Juba KM, Weiland D. Seizure management in a complex hospice patient. Journal of Pain and Palliative Care Pharmacotherapy 2010;24:27-32. 47. Josephson F. Drug-drug interactions in the treatment of HIV infection: Focus on pharmacokinetic enhancement through CYP3A inhibition. Journal of Internal Medicine 2010;268:530-539. 48. Josefsson L, Dahl V, Palmer S. Can HIV infection be eradicated through use of potent antiviral agents? Current Opinion in Infectious Diseases 2010;23:628-632. 49. Ingelman-Sundberg M, Sim SC. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochemical and Biophysical Research Communications 2010;396:90-94. 50. Hofbauer LC, Hamann C, Ebeling PR. Approach to the patient with secondary osteoporosis. European Journal of Endocrinology 2010;162:1009-1020. 51. Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Current HIV/AIDS Reports 2010;7:152-160. 52. Giraud C, Manceau S, Treluyer JM. ABC transporters in human lymphocytes: Expression, activity and role, modulating factors and consequences for antiretroviral therapies. Expert Opinion on Drug Metabolism and Toxicology 2010;6:571-589. 53. Gervasini G, Benitez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. European Journal of Clinical Pharmacology 2010;66:755-774. 54. Ferner RE, Aronson JK. Pharmacogenetics and adverse drug reactions. Adverse Drug Reaction Bulletin 2010:1015-1018. 55. Fernandez-Morato J, Vila BA, Gomez-Ulloa D, Quer ME. News in pediatric drug development in Spain in 2009. [Catalan]. Pediatria Catalana 2010;70:81-94. 56. Feeney ER, Mallon PWG. Impact of mitochondrial toxicity of HIV-1 antiretroviral drugs on lipodystrophy and metabolic dysregulation. Current Pharmaceutical Design 2010;16:3339-3351. 57. Etgen T, Eberl B, Freudenberger T. Anti-retroviral therapy-induced status epilepticus in "pseudo-HIV serodeconversion". General Hospital Psychiatry 2010;32:559-559. 58. Diederich M, Chateauvieux S, Morceau F, Dicato M. Molecular and therapeutic potential and toxicity of valproic acid. Journal of Biomedicine and Biotechnology 2010;2010. 59. Deeks ED, Perry CM. Efavirenz/emtricitabine/tenofovir disoproxil fumarate

single-tablet regimen (atripla): A review of its use in the management of HIV infection. Drugs 2010;70:2315-2338. 60. De AM, Dallanoce C, Holzgrabe U, Trankle C, Mohr K. Allosteric ligands for G protein-coupled receptors: A novel strategy with attractive therapeutic opportunities. Medicinal Research Reviews 2010;30:463-549. 61. Davis S. Diabetogenic drugs: Treating chronic conditions to minimise new onset diabetes. SA Pharmaceutical Journal 2010;77:22-33. 62. Darnag R, Schmitzer A, Belmiloud Y, et al. Quantitative structure-activity relationship studies of TIBO derivatives using support vector machines. SAR and QSAR in Environmental Research 2010;21:231-246. 63. Curran A, Gutirerrez M, Deig E, et al. Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. Journal of Antimicrobial Chemotherapy 2010;65:2195-2203. 64. Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. Journal of Allergy and Clinical Immunology 2010;125:S195-S203. 65. Burger DM. Raltegravir: A review of its pharmacokinetics, pharmacology and clinical studies. Expert Opinion on Drug Metabolism and Toxicology 2010;6:1151-1160. 66. Bhattacharya M, Rajeshwari K, Dhingra B. Posaconazole. Journal of Postgraduate Medicine 2010;56:163-167. 67. Benton TD. Treatment of psychiatric disorders in children and adolescents with HIV/AIDS. Current Psychiatry Reports 2010;12:104-110. 68. Basu D. Overview of substance abuse and hepatitis C virus infection and co-infections in India. Journal of Neuroimmune Pharmacology 2010;5:496-506. 69. Barber TJ, Benn PD. Postexposure prophylaxis for HIV following sexual exposure. Current Opinion in HIV and AIDS 2010;5:322-326. 70. Baker D. Current FDA-Related drug information - New drugs approved by the FDA; New dosage forms and indications approved by the FDA; Agents pending FDA approval; New drug/biologics license applications filed by manufacturer; Supplemental applications filed by manufacturer; Significant labeling changes or "dear health professional" Letters related to safety. Hospital Pharmacy 2010;45:153-164. 71. Arendt G, Nolting T. Psychiatric diseases in HIV-positive patients. [German]. Arzneimitteltherapie 2010;28:269-276. 72. Archin NM, Cheema M, Parker D, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS ONE 2010;5. 73. Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. The Lancet 2010;376:367-387. 74. Adams J, Patel N, Mankaryous N, Tadros M, Miller CD. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Annals of Pharmacotherapy 2010;44:157-165. 75. Road rules for drugs: A survey of signals. Nature Medicine 2010;16:1362-1363. 76. Forum. Pharmaceutical Medicine 2010;24:45-57. 77. Zhou SF, Liu JP, Lai XS. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Current Medicinal Chemistry 2009;16:2661-2805.

78. Zhang W, Han Y, Siok LL, Lee YL. Dietary regulation of P-gp function and expression. Expert Opinion on Drug Metabolism and Toxicology 2009;5:789-801. 79. Worobec SM. Treatment of leprosy/Hansen's disease in the early 21st century. Dermatologic Therapy 2009;22:518-537. 80. Wilson LE, Gallant JE. The management of treatment-experienced HIV-infected patients: New drugs and drug combinations. Clinical Infectious Diseases 2009;48:214-221. 81. Wiffen PJ, Rees J. Lamotrigine for acute and chronic pain. Cochrane Database of Systematic Reviews 2009. 82. Wiech NL, Fisher JF, Helquist P, Wiest O. Inhibition of histone deacetylases: A pharmacological approach to the treatment of non-cancer disorders. Current Topics in Medicinal Chemistry 2009;9:257-271. 83. Webb KM, Mactutus CF, Booze RM. The ART of HIV therapies: Dopaminergic deficits and future treatments for HIV pediatric encephalopathy. Expert Review of Anti-Infective Therapy 2009;7:193-203. 84. Weaver J, Grenade LL, Kwon H, Avigan M. Finding, evaluating, and managing drug-related risks: Approaches taken by the US food and drug administration (FDA). Dermatologic Therapy 2009;22:204-215. 85. Vlassova N, Angelino AF, Treisman GJ. Update on mental health issues in patients with HIV infection. Current Infectious Disease Reports 2009;11:163-169. 86. Turowski CB, Ross AS, Cusack CA. Human papillomavirus-associated squamous cell carcinoma of the nail bed in African-American patients. International Journal of Dermatology 2009;48:117-120. 87. Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News and Perspectives 2009;22:119-125. 88. Throm S. Activities of the Committee for Medicinal Products for Human Use. [German]. Pharmazeutische Industrie 2009;71:1546-1554. 89. Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: Possible mechanisms and management. American Journal of Hematology 2009;84:428-434. 90. Takahashi E, Niimi K. Modulators of voltage-dependent calcium channels for the treatment of nervous system diseases. Recent Patents on CNS Drug Discovery 2009;4:96-111. 91. Speth C, Rambach G, Sopper S. Complement and microglia in the neuropathogenesis of HIV infection: pro- and anti-inflammatory aspects. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry 2009;8:131-152. 92. Sloss A, Kubler P. Prescribing in liver disease. Australian Prescriber 2009;32:32-35. 93. Serafin A, Stanczak A. Different concepts of drug delivery in disease entities. Mini-Reviews in Medicinal Chemistry 2009;9:481-497. 94. Scott KM, Parker F, Heckmann JM. Opsoclonus-myoclonus syndrome and HIV-infection. Journal of the Neurological Sciences 2009;284:192-195. 95. Schiller DS, Youssef-Bessler M. Etravirine: A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clinical Therapeutics 2009;31:692-704. 96. Schestatsky P, Nascimento OJM. What do general neurologists need to know

about neuropathic pain? Arquivos de Neuro-Psiquiatria 2009;67:741-749. 97. Sayana S, Khanlou H. Maraviroc: A new CCR5 antagonist. Expert Review of Anti-Infective Therapy 2009;7:9-19. 98. Rotili D, Simonetti G, Savarino A, Palamara AT, Migliaccio AR, Mai A. Non-cancer uses of histone deacetylase inhibitors: Effects on infectious diseases and beta-hemoglobinopathies. Current Topics in Medicinal Chemistry 2009;9:272-291. 99. Robinson-Papp J, Simpson DM, Stucky S. Neuromuscular diseases associated with HIV-1 infection. Muscle and Nerve 2009;40:1043-1053. 100. Rivas P, Morello J, Garrido C, Rodriguez-Novoa S, Soriano V. Role of atazanavir in the treatment of HIV infection. Therapeutics and Clinical Risk Management 2009;5:99-116. 101. Reuse S, Calao M, Kabeya K, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: Implications for treatment of latent infection. PLoS ONE 2009;4. 102. Power C, Boisse L, Rourke S, Gill M. NeuroAIDS: An evolving epidemic. Canadian Journal of Neurological Sciences 2009;36:285-295. 103. Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy 2009;29:1386-1391. 104. Phillips EJ, Mallal SA. HLA and drug-induced toxicity. Current Opinion in Molecular Therapeutics 2009;11:231-242. 105. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: The abacavir example. Molecular Diagnosis and Therapy 2009;13:1-9. 106. Pfeffer G, Prout A, Hooge J, Maguire J. Biopsy-proven immune reconstitution syndrome in a patient with AIDS and cerebral toxoplasmosis. Neurology 2009;73:321-322. 107. Pereira CV, Moreira AC, Pereira SP, et al. Investigating drug-induced mitochondrial toxicity: A biosensor to increase drug safety? Current Drug Safety 2009;4:34-54. 108. Owe-Larsson B, Sall L, Salamon E, Allgulander C. HIV infection and psychiatric illness. African Journal of Psychiatry (South Africa) 2009;12:115-128. 109. Nivoix Y, Ubeaud-Sequier G, Engel P, Leveque D, Herbrecht R. Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Current Drug Metabolism 2009;10:395-409. 110. Neely M, Kovacs A. Managing treatment-experienced pediatric and adolescent Hiv patients: Role of darunavir. Therapeutics and Clinical Risk Management 2009;5:595-615. 111. Navarro V, Mazoit JX. Drugs for status epilepticus treatment. [French]. Revue Neurologique 2009;165:355-365. 112. Moretta G, Pettinicchi JP, Talarico ME, et al. Clinical reasoning: A 35-year-old man with a right hemiplegia and a cerebral mass. Neurology 2009;73:e35-e38. 113. Momin SB, del Rosso JQ. Review of intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Clinical and Aesthetic Dermatology 2009;2:11-12. 114. Moling O, Rimenti G, Pristera R, et al. Fatal lactic acidosis precipitated by nifedipine in a patient treated with disulfiram and antiretrovirals. Drug Metabolism

Letters 2009;3:176-180. 115. Mo SL, Liu YH, Duan W, Wei MQ, Kanwar JR, Zhou SF. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Current Drug Metabolism 2009;10:730-753. 116. McKeage K, Perry CM, Keam SJ. Darunavir: A Review of its Use in the Management of HIV Infection in Adults. Drugs 2009;69:477-503. 117. McCombe JA, Auer RN, Maingat FG, Houston S, Gill MJ, Power C. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: Outcome and epidemiology. Neurology 2009;72:835-841. 118. Martinez R, De CG, Machado AA, Moya MJ. Case report primary aspergilloma and subacute invasive aspergillosis in two AIDS patients. Revista do Instituto de Medicina Tropical de Sao Paulo 2009;51:49-52. 119. MacDonald L, Murty M, Foster BC. Antiviral drug disposition and natural health products: Risk of therapeutic alteration and resistance. Expert Opinion on Drug Metabolism and Toxicology 2009;5:563-578. 120. Lux J, Brogan K. Management of common psychiatric conditions in the HIV-positive population. Current HIV/AIDS Reports 2009;6:108-115. 121. Lakhman SS, Ma Q, Morse GD. Pharmacogenomics of CYP3A: Considerations for HIV treatment. Pharmacogenomics 2009;10:1323-1339. 122. Kraft-Terry SD, Buch SJ, Fox HS, Gendelman HE. A Coat of Many Colors: Neuroimmune Crosstalk in Human Immunodeficiency Virus Infection. Neuron 2009;64:133-145. 123. Kmmerle T, Lehmann C, Hartmann P, Wyen C, Fatkenheuer G. Vicriviroc: A CCR5 antagonist for treatment-experienced patients with HIV-1 infection. Expert Opinion on Investigational Drugs 2009;18:1773-1785. 124. Kavirajan H. Memantine: A comprehensive review of safety and efficacy. Expert Opinion on Drug Safety 2009;8:89-109. 125. Kaul M. HIV-1 associated dementia: Update on pathological mechanisms and therapeutic approaches. Current Opinion in Neurology 2009;22:315-320. 126. Katlama C, Murphy R. Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection. Therapeutics and Clinical Risk Management 2009;5:331-340. 127. Kamat TS, Rataboli PV, Phirke VR, Mangrule SA. Recent advances in antiretroviral therapy. Journal of Clinical and Diagnostic Research 2009;3:1805-1812. 128. Jorgensen JT, Winther H. The new era of personalized medicine: 10 years later. Personalized Medicine 2009;6:423-428. 129. Johnson LB, Saravolatz LD. Etravirine, a next-generation nonnucleoside reverse- transcriptase inhbitor. Clinical Infectious Diseases 2009;48:1123-1128. 130. Jeffrey CP, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nature Reviews Drug Discovery 2009;8:41-54. 131. Husstedt IW, Reichelt D, Neuen-Jakob E, et al. Neurotoxicity and side-effects of Highly Active Antiretroviral Therapy [HAART] on the central and peripheral nerve system. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry 2009;8:192-201. 132. Husstedt IW, Reichelt D, Neuen-Jakob E, et al. Highly active antiretroviral

therapy of neuro-AIDS : SSSide effects on the nervous system and interactions. [German]. Nervenarzt 2009;80:1133-1142. 133. Husstedt IW, Reichelt D, Kastner F, Evers S, Hahn K. Epidemiology and therapy of pain and depression during HIV and AIDS. [German]. Schmerz 2009;23:628-639. 134. Hunt JS, Romanelli F. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. Pharmacotherapy 2009;29:295-304. 135. Hudcova J, Talmor D. Life-threatening hemorrhage following subcutaneous heparin therapy. Therapeutics and Clinical Risk Management 2009;5:51-54. 136. Holland DP, Hamilton CD, Weintrob AC, et al. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy 2009;29:503-510. 137. Hoffman JM, Shah ND, Vermeulen LC, et al. Projecting future drug expenditures-2009. American Journal of Health-System Pharmacy 2009;66:237-257. 138. Hicks C, Gulick RM. Raltegravir: The first HIV Type 1 Integrase Inhibitor. Clinical Infectious Diseases 2009;48:931-939. 139. Heller FR, Dupont AG. Generics: Need for clinical concern? Acta Clinica Belgica 2009;64:415-422. 140. Hatherill S, Flisher A. Delirium in children with HIV/AIDS. Journal of Child Neurology 2009;24:879-883. 141. Hall Ii RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: Current standards and recent advances - Insights from the society of infectious diseases pharmacists. Pharmacotherapy 2009;29:1468-1481. 142. Haanpaa ML, Backonja MM, Bennett MI, et al. Assessment of Neuropathic Pain in Primary Care. American Journal of Medicine 2009;122:S13-S21. 143. Grattagliano I, Bonfrate L, Diogo CV, Wang HH, Wang DQH, Portincasa P. Biochemical mechanisms in drug-induced liver injury: Certainties and doubts. World Journal of Gastroenterology 2009;15:4865-4876. 144. Golz J, Krausz M. Therapy of chronic HCV-infection in psychotic drug users from clinical perspective. [German]. Suchtmedizin in Forschung und Praxis 2009;11:271-276. 145. Gebo KA, Justice A. HIV infection in the elderly. Current Infectious Disease Reports 2009;11:246-254. 146. Focosi D, Azzara A, Kast RE, Carulli G, Petrini M. Lithium and hematology: Established and proposed uses. Journal of Leukocyte Biology 2009;85:20-28. 147. Ferrando SJ. Psychopharmacologic treatment of patients with HIV/AIDS. Current Psychiatry Reports 2009;11:235-242. 148. Farrer F. New drugs 2008 - A brief review. SA Pharmaceutical Journal 2009;76:22-26. 149. Evans HER, Tsourapas A, Mercer CH, et al. Primary care consultations and costs among HIV-positive individuals in UK primary care 1995-2005: A cohort study. Sexually Transmitted Infections 2009;85:543-549. 150. DiazGranados CA, Saavedra-Trujillo CH, Mantilla M, Valderrama SL, Alquichire C, Franco-Paredes C. Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. The Lancet Infectious Diseases 2009;9:324-330. 151. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: Treatment

considerations and research outlook. Current Opinion in Oncology 2009;21:445-454. 152. Crews L, Patrick C, Achim CL, Everall IP, Masliah E. Molecular pathology of neuro-aids (CNS-HIV). International Journal of Molecular Sciences 2009;10:1045-1063. 153. Colin L, Van LC. Molecular control of HIV-1 postintegration latency: Implications for the development of new therapeutic strategies. Retrovirology 2009;6. 154. Colby-Germinario S, Rios A, Quesada J, et al. HIV inactivation by cross-linking of photo-labeled anti-retroviral compounds with HIV reverse transcriptase. Vaccine 2009;27:6137-6142. 155. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nature Reviews Microbiology 2009;7:798-812. 156. Carl J, Hill DA. Preconception counseling: Make it part of the annual exam. Journal of Family Practice 2009;58:307-314. 157. Briemberg HR. Peripheral nerve complications of medical disease. Seminars in Neurology 2009;29:124-135. 158. Blank A, Hellstern V, Schuster D, et al. Efavirenz treatment and false-positive results in benzodiazepine screening tests. Clinical Infectious Diseases 2009;48:1787-1789. 159. Bhattacharya S, Osman H. Novel targets for anti-retroviral therapy. Journal of Infection 2009;59:377-386. 160. Bentu-Ferrer D, Arvieux C, Tribut O, Ruffault A, Bellissant E. Clinical pharmacology, efficacy and safety of atazanavir: A review. Expert Opinion on Drug Metabolism and Toxicology 2009;5:1455-1468. 161. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Seminars in Liver Disease 2009;29:337-347. 162. Barton B, Zauber SE, Goetz CG. Movement disorders caused by medical disease. Seminars in Neurology 2009;29:97-110. 163. Andreu I, Mayorga C, Miranda MA. Metabolomics in drug intolerance. Current Drug Metabolism 2009;10:947-955. 164. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Current Drug Metabolism 2008;9:310-322. 165. Zaborowski D, Beniowski M. Low level viremia on HAART and newly registered protease inhibitor - A case report. HIV and AIDS Review 2008;7:29-31. 166. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clinical Pharmacokinetics 2008;47:351-371. 167. Waters L. HIV therapy - Past, present and future. Drug Discovery World 2008;9:11-18. 168. Wallace VCJ, Segerdahl AR, Blackbeard J, Pheby T, Rice ASC. Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain. Neuroscience Letters 2008;448:153-156. 169. Vogler MA. Severe headaches and cerebrovascular disease in a young man with perinatally acquired HIV infection. AIDS Reader 2008;18:354-365. 170. Venkat A, Piontkowsky DM, Cooney RR, Srivastava AK, Suares GA, Heidelberger CP. Care of the HIV-Positive Patient in the Emergency Department in the Era of Highly Active Antiretroviral Therapy. Annals of Emergency Medicine

2008;52:274-285. 171. Uthman OA, Abdulmalik JO. Adjunctive therapies for AIDS dementia complex. Cochrane Database of Systematic Reviews 2008. 172. Trueb RM. Hypertrichosis. [German]. Hautarzt 2008;59:325-338. 173. Tomillero A, Moral MA. Gateways to clinical trials. Methods and Findings in Experimental and Clinical Pharmacology 2008;30:643-672. 174. Terrie YC. New treatments winning against HIV. Pharmacy Times 2008;74:24-25. 175. Temesgen Z, Siraj DS. Raltegravir: First in class HIV integrase inhibitor. Therapeutics and Clinical Risk Management 2008;4:493-500. 176. Taylor JM, Nicot C. HTLV-1 and apoptosis: Role in cellular transformation and recent advances in therapeutic approaches. Apoptosis 2008;13:733-747. 177. Struble KA, Reynolds KS. A regulatory perspective on the role of drug interactions in antiretroviral drug development. Current Opinion in HIV and AIDS 2008;3:325-329. 178. Strassburg CP, Kalthoff S, Ehmer U. Variability and function of family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A). Critical Reviews in Clinical Laboratory Sciences 2008;45:485-530. 179. Stellbrink HJ. Raltegravir in the management of HIV-infected patients. Drug Design, Development and Therapy 2008:281-288. 180. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-Reduced Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation for Human Immunodeficiency Virus-Associated Lymphoma: AIDS Malignancy Consortium Study 020. Biology of Blood and Marrow Transplantation 2008;14:59-66. 181. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS 2008;22:1-13. 182. Soriano V, Geretti AM, Perno CF, et al. Optimal use of maraviroc in clinical practice. AIDS 2008;22:2231-2240. 183. Simone MJ, Appelbaum J. HIV in older adults. Geriatrics 2008;63:6-12. 184. Shear NH, Milpied B, Bruynzeel DP, Phillips EJ. A review of drug patch testing and implications for HIV clinicians. AIDS 2008;22:999-1007. 185. Schulenburg E, Le Roux PJ. Antiretroviral therapy and anaesthesia. Southern African Journal of Anaesthesia and Analgesia 2008;14:31-38. 186. Satishchandra P, Sinha S. Seizures in HIV-seropositive individuals: NIMHANS experience and review. Epilepsia 2008;49:33-41. 187. Sapre NS, Pancholi N, Gupta S, Sapre N. Computational modeling of tetrahydroimidazo-[4,5,1-jk][1,4]- benzodiazepinone derivatives: An atomistic drug design approach using Kier-Hall electrotopological state (E-state) indices. Journal of Computational Chemistry 2008;29:1699-1706. 188. Sagot-Lerolle N, Lamine A, Chaix ML, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (London, England) 2008;22:1125-1129. 189. Rumbaugh JA, Steiner J, Sacktor N, Nath A. Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction. Future HIV Therapy 2008;2:271-280. 190. Robinson-Papp J, Simpson DM. Neuromuscular Complications of Human

Immunodeficiency Virus Infection. Physical Medicine and Rehabilitation Clinics of North America 2008;19:81-96. 191. Rezk NL, White N, Kashuba ADM. An accurate and precise high-performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction. Analytica Chimica Acta 2008;628:204-213. 192. Repetto MJ, Petitto JM. Psychopharmacology in HIV-infected patients. Psychosomatic Medicine 2008;70:585-592. 193. Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: Design and clinical applications. Nature Reviews Drug Discovery 2008;7:255-270. 194. Peytavin G. Clinical pharmacokinetic of maraviroc. [French]. Medecine et Maladies Infectieuses 2008;38:12-16. 195. Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: Are we there yet? Pharmacotherapy 2008;28:755-768. 196. Pawinski T, Pulik P, Gralak B, Horban A. Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy. Acta Poloniae Pharmaceutica - Drug Research 2008;65:93-100. 197. Pau AK. Clinical management of drug interaction with antiretroviral agents. Current Opinion in HIV and AIDS 2008;3:319-324. 198. Nowak K, Szpakiewicz B. Synthesis of new imidazole derivatives. Journal of Heterocyclic Chemistry 2008;45:1247-1250. 199. Nijhawan AE, Zachary KC, Kwara A, Venna N. Status epilepticus resulting from severe efavirenz toxicity in an HIV-infected patient. AIDS Reader 2008;18:386-388+C383. 200. Nichols WG, Peck Campbell AJ, Boeckh M. Respiratory viruses other than influenza virus: Impact and therapeutic advances. Clinical Microbiology Reviews 2008;21:274-290. 201. Newman W. Removing barriers to a clinical pharmacogenetics service. Personalized Medicine 2008;5:471-480. 202. Nellen JFJB, Damming M, Godfried MH, et al. Steady-state nevirapine plasma concentrations are influenced by pregnancy. HIV Medicine 2008;9:234-238. 203. Mocchetti I, Bachis A, Masliah E. Chemokine receptors and neurotrophic factors: Potential therapy against AIDS dementia? Journal of Neuroscience Research 2008;86:243-255. 204. Minuto JJ, Haubrich R. Etravirine: A second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection. Future HIV Therapy 2008;2:525-537. 205. Meyer HP. Neuropathic pain - Current concepts. South African Family Practice 2008;50:40-49. 206. Mellgren A. Preventing brain damage in HIV infection. Future Neurology 2008;3:565-574. 207. Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: Prospective observational study. British Journal of Clinical Pharmacology 2008;65:396-406.

208. McNicholl IR. Strategies to enhance adherence, reduce costs, and improve patient quality of life. Journal of Managed Care Pharmacy 2008;14:S12-S16. 209. Mathews KD, Stark JE. Hyperchloremic, normal anion-gap, metabolic acidosis due to topiramate. American Journal of Health-System Pharmacy 2008;65:1430-1434. 210. Mancano MA. New drugs of 2007. Pharmacy Times 2008;74:75-82. 211. Mallolas J, Laguno M. Pegylated IFN-alpha2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV. Expert Review of Anti-Infective Therapy 2008;6:281-289. 212. MacArthur RD, Novak RM. Maraviroc: The first of a new class of antiretroviral agents. Clinical Infectious Diseases 2008;47:236-241. 213. Lopez-Cortes LF. Pharmacology, pharmacokinetic features and interactions of atazanavir. [Spanish]. Enfermedades Infecciosas y Microbiologia Clinica 2008;26:2-8. 214. Lana SR, Lerida AI, Mendoza JL. Treatment of neuropathic pain in HIV-infected patients. [Spanish]. Enfermedades Infecciosas y Microbiologia Clinica 2008;26:348-355. 215. Kuwahara T, Nakakura T, Oda S, et al. Problems in three Japanese drug users with Human Immunodeficiency Virus infection. Journal of Medical Investigation 2008;55:156-160. 216. Knox TA, Oleson L, Von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. Journal of Acquired Immune Deficiency Syndromes 2008;49:358-368. 217. Klopstock T. Drug-induced myopathies. Current Opinion in Neurology 2008;21:590-595. 218. Katende-Kyenda NL, Lubbe MS, Serfontein JHP, Truter I. Effect of prescribed minimum benefits on the prevalence of possible drug - Drug interactions of antiretroviral agents in a section of the private health care sector in South Africa: A 2 year comparative study. International Journal of Pharmacy Practice 2008;16:403-408. 219. Katende-Kyenda NL, Lubbe MS, Serfontein JHP, Truter I. Prevalence of drug-drug interactions of antiretroviral agents in the private health care sector in South Africa. South African Medical Journal 2008;98:109-113. 220. Johnson WW. Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: Therapeutic relevance. Drug Metabolism Reviews 2008;40:101-147. 221. Iwamoto M, Kassahun K, Troyer MD, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: In vitro/in vivo correlation. Journal of Clinical Pharmacology 2008;48:209-214. 222. Hegarty AM, Chaudhry SI, Hodgson TA. Oral healthcare for HIV-infected patients: An international perspective. Expert Opinion on Pharmacotherapy 2008;9:387-404. 223. Hall WA, Truwit CL. The surgical management of infections involving the cerebrum. Neurosurgery 2008;62:SHC519-SHC530. 224. Gueant JL, Gueant-Rodriguez RM, Gastin IA, et al. Pharmacogenetic determinants of immediate and delayed reactions of Drug hypersensitivity. Current Pharmaceutical Design 2008;14:2770-2777. 225. Groci JD, Colacino JM, Peltz SW, Dougherty JP, Gu Z. HIV type-1 latency: Targeted induction of proviral reservoirs. Antiviral Chemistry and Chemotherapy 2008;19:177-187. 226. Grant PM, Zolopa A. Integrase inhibitors: A clinical review of raltegravir and

elvitegravir. Journal of HIV Therapy 2008;13:36-39. 227. Grande F, Garofalo A, Neamati N. Small molecules anti-HIV therapeutics targeting CXCR4. Current Pharmaceutical Design 2008;14:385-404. 228. Gonzalez-Duarte A, Robinson-Papp J, Simpson DM. Diagnosis and Management of HIV-Associated Neuropathy. Neurologic Clinics 2008;26:821-832. 229. Goiriz R, Fernandez HJ. Cutaneous drug reactions in acquired immune deficiency syndrome. [Spanish]. Piel 2008;23:303-308. 230. Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics 2008;9:207-214. 231. Gallagher DP, Kieran J, Sheehan G, Lambert J, Mahon N, Mallon PWG. Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 Case reports. Clinical Infectious Diseases 2008;47:e36-e38. 232. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: Implications for drug interactions. Annals of Pharmacotherapy 2008;42:1048-1059. 233. Ferrando SJ, Freyberg Z. Neuropsychiatric Aspects of Infectious Diseases. Critical Care Clinics 2008;24:889-919. 234. Evering TH, Markowitz M. Raltegravir: An integrase inhibitor for HIV-1. Expert Opinion on Investigational Drugs 2008;17:413-422. 235. Dumais G, Iovu M, du SP. Inflammatory reactions and drug response: Importance of cytochrome P450 and membrane transporters. Expert Review of Clinical Pharmacology 2008;1:627-647. 236. DiCenzo R, Peterson DR, Cruttenden K, et al. Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. Antimicrobial Agents and Chemotherapy 2008;52:3035-3039. 237. Diaz RAS, Sancho J, Serratosa J. Antiepileptic drug interactions. Neurologist 2008;14:S55-S65. 238. Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John's wort and implication in drug development. Current Pharmaceutical Design 2008;14:1723-1742. 239. Desai J. Perspectives on interactions between antiepileptic drugs (AEDs) and antimicrobial agents. Epilepsia 2008;49:47-49. 240. Deeks ED, Keating GM. Etravirine. Drugs 2008;68:2357-2372. 241. De CE. Antivirals: Current state of the art. Future Virology 2008;3:393-405. 242. Cruz AT, Starke JR. Treatment of tuberculosis in children. Expert Review of Anti-Infective Therapy 2008;6:939-957. 243. Crews L, Lentz MR, Gonzalez RG, Fox HS, Masliah E. Neuronal injury in simian immunodeficiency virus and other animal models of neuroAIDS. Journal of NeuroVirology 2008;14:327-339. 244. Correll T, Klibanov OM. Integrase inhibitors: A new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy 2008;28:90-101. 245. Cohen SD, Chawla LS, Kimmel PL. Acute kidney injury in patients with human immunodeficiency virus infection. Current Opinion in Critical Care 2008;14:647-653. 246. Clarke A, Stein CR, Townsend ML. Drug-drug interactions with HIV antiretroviral therapy. U 2008;Pharmacist. 33:HS-HS. 247. Chubineh S, McGowan J. Nausea and vomiting in HIV: A symptom review.

International Journal of STD and AIDS 2008;19:723-728. 248. Cheng K, Masters S, Stephenson T, et al. Identification of suspected fatal adverse drug reactions by paediatricians: A UK surveillance study. Archives of Disease in Childhood 2008;93:609-611. 249. Charlton RA, Cunnington MC, De Vries CS, Weil JG. Data resources for investigating drug exposure during pregnancy and associated outcomes: The General Practice Research Database (GPRD) as an alternative to pregnancy registries. Drug Safety 2008;31:39-51. 250. Castro BA. The immunocompromised pediatric patient and surgery. Best Practice and Research: Clinical Anaesthesiology 2008;22:611-626. 251. Castillejos-Lopez Md, Garcia-Sancho M, Quinones-Falconi F, Perez-Padilla JR. Cytochrome P450 and NAT2 polymorphisms and drug metabolism in DOTS. [Spanish]. Revista de Investigacion Clinica 2008;60:47-57. 252. Cada DJ, Levien T, Baker DE. Etravirine. Hospital Pharmacy 2008;43:498-510. 253. Bruce RD, Altice FL, Friedland GH. Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: Implications and management for clinical practice. Expert Review of Clinical Pharmacology 2008;1:115-127. 254. Boisse L, Gill MJ, Power C. HIV Infection of the Central Nervous System: Clinical Features and Neuropathogenesis. Neurologic Clinics 2008;26:799-819. 255. Boesecke C, Cooper DA. Toxicity of HIV protease inhibitors: Clinical considerations. Current Opinion in HIV and AIDS 2008;3:653-659. 256. Blinder V, Fisher SG. The role of environmental factors in the etiology of lymphoma. Cancer Investigation 2008;26:306-316. 257. Barragan P, Podzamczer D. Lopinavir/ritonavir: A protease inhibitor for HIV-1 treatment. Expert Opinion on Pharmacotherapy 2008;9:2363-2375. 258. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. American Journal of the Medical Sciences 2008;335:126-136. 259. Asplin JR. Evaluation of the Kidney Stone Patient. Seminars in Nephrology 2008;28:99-110. 260. Arolker MS, Johnson MJ. Palliative care in non-malignant disease. Medicine 2008;36:96-99. 261. Arnedo VM. HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance. [Spanish]. Enfermedades Infecciosas y Microbiologia Clinica 2008;26:34-39. 262. Archin NM, Eron JJ, Palmer S, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 2008;22:1131-1135. 263. Archin NM, Eron JJ, Palmer S, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (London, England) 2008;22:1131-1135. 264. Amur S, Frueh FW, Lesko LJ, Huang SM. Integration and use of biomarkers in drug development, regulation and clinical practice: A US regulatory perspective. Biomarkers in Medicine 2008;2:305-311. 265. Ambrogio AG, Giraldi FP, Cavagnini F. Drugs and HPA axis. Pituitary 2008;11:219-229.

266. Alsina MMP, Tuset CM, Miro JM. Pharmacokinetics and interactions of raltegravir. [Spanish]. Enfermedades Infecciosas y Microbiologia Clinica 2008;26:23-28. 267. Allport J. Incidence and prevalence of medication-induced osteoporosis: Evidence-based review. Current Opinion in Rheumatology 2008;20:435-441. 268. Alfirevic A, Pirmohamed M. Adverse drug reactions and pharmacogenomics: Recent advances. Personalized Medicine 2008;5:11-23. 269. Wiffen P, Rees J. Lamotrigine for acute and chronic pain. Cochrane Database of Systematic Reviews 2007. 270. Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Expert Opinion on Drug Metabolism and Toxicology 2007;3:583-598. 271. Ryder NS. Discontinued drugs in 2006: Anti-infectives. Expert Opinion on Investigational Drugs 2007;16:1867-1878. 272. Reid S, McGrath L. Hiv/aids. Sleep Medicine Clinics 2007;2:51-58. 273. Reddy AC, Sudhir B, Ismail B, Ganesan L, Marur S. Pneumocystosis of the brain presenting as ring-enhancing lesions. Infections in Medicine 2007;24:137-138a. 274. Luna B, Townsend M. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clinical Therapeutics 2007;29:2309-2318. 275. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: An overview. Expert Opinion on Drug Safety 2007;6:673-684. 276. Hughes CA, Freitas A, Miedzinski LJ. Interaction between lopinavir/ritonavir and warfarin. CMAJ 2007;177:357-359. 277. Houlton S. NCEs tackle lifestyle diseases. Manufacturing Chemist 2007;78:29-32. 278. Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: Implications for drug therapy. Expert Opinion on Drug Metabolism and Toxicology 2007;3:557-571. 279. Grossman I. Routine pharmacogenetic testing in clinical practice: Dream or reality? Pharmacogenomics 2007;8:1449-1459. 280. Giunta B, Somboonwit C, Nikolic WV, et al. Psychiatric implications of hepatitis-C infection. Critical Reviews in Neurobiology 2007;19:79-118. 281. El-Atrouni WI, Temesgen Z. Darunavir. Drugs of Today 2007;43:671-679. 282. Collazos J. Sexual dysfunction in the highly active antiretroviral therapy era. AIDS Reviews 2007;9:237-245. 283. Shehu BB, Mahmud MR, Ismail NJ. Neurosurgical infections. Nigerian Journal of Surgical Research 2006;8:1-18. 284. Kellam P. Attacking pathogens through their hosts. Genome Biology 2006;7. 285. Cairns JS. Review of "The Twelfth West Cost Retrovirous Meeting" and "The Twenty-third Annual Symposium on Nonhuman Primate Models for AIDS". AIDS Research and Therapy 2006;3.

Medline (Citations entry year from 2008-2010) Date Searched: January 07, 2011 Search Topic: Updated lit search, interaction between ARVs and AEDs

1

EBM Reviews - Cochrane Central Register of Controlled Trials 4th Quarter 2010

# Searches Results Search Type

HIV and related terms component

1 HIV Infections/ 3751 Advanced

2 exp HIV/ 1830 Advanced

3 Acquired Immunodeficiency Syndrome/ 977 Advanced

4 human immunodeficiency virus*.tw. 1957 Advanced

5 AIDS Dementia Complex/ 45 Advanced

6 (aids adj2 dementia adj2 complex).tw. 14 Advanced

7 HIV.tw. 6024 Advanced

8 (acquired adj2 immunodeficiency adj2 syndrome?).tw. 321 Advanced

9 or/1-8 7058 Advanced

ARVs and related terms component

10 Anti-Retroviral Agents/ 123 Advanced

11 Anti-HIV Agents/ 1414 Advanced

12 Delavirdine/ 26 Advanced

13 Didanosine/ 278 Advanced

14 Lamivudine/ 603 Advanced

15 Nevirapine/ 217 Advanced

16 Stavudine/ 191 Advanced

17 Zidovudine/ 810 Advanced

18 azt.tw. 167 Advanced

19 abacavir.mp. 174 Advanced

20 amprenavir.mp. 77 Advanced


2

21 atazanavir.mp. 66 Advanced

22 darunavir.mp. 41 Advanced

23 efavirenz.mp. 269 Advanced

24 efv.tw. 72 Advanced

25 emtricitabine.mp. 94 Advanced

26 enfuvirtide.tw. 52 Advanced

27 etravirine.mp. 25 Advanced

28 TMC125.tw. 18 Advanced

29 fosamprenavir.mp. 26 Advanced

30 Indinavir/ 163 Advanced

31 Ritonavir/ 358 Advanced

32 riton?vir.mp. 523 Advanced

33 Nelfinavir/ 110 Advanced

34 raltegravir.mp. 25 Advanced

35 Saquinavir/ 133 Advanced

36 tenofovir.mp. 186 Advanced

37 tdf.tw. 115 Advanced

38 tipranavir.mp. 24 Advanced

39 d4T.tw. 112 Advanced

40 (Delavirdine or Didanosine or Lamivudine or Nevirapine).mp.

1592 Advanced

41 (Stavudine or Zidovudine or Indinavir or Nelfinavir).mp. 1528 Advanced

42 Saquinavir.mp. 199 Advanced

43 arv.tw. 56 Advanced

44 (antiretroviral* or anti retroviral*).mp. 2087 Advanced


3


46 9 or 45 7867 Advanced

AEDs and related terms component

47 Anticonvulsants/ 1483 Advanced

48 aed.tw. 222 Advanced

49 (antiepileptic* or anticonvulsant*).mp. 2131 Advanced

50 carbamazepine/ 619 Advanced

51 clonazepam/ 113 Advanced

52 ethosuximide/ 9 Advanced

53 phenobarbital/ 384 Advanced

54 phenytoin/ 460 Advanced

55 primidone/ 43 Advanced

56 valproic acid/ 526 Advanced

57 vigabatrin/ 101 Advanced

58 phenobarbitone.mp. 134 Advanced

59 oxcarbazepine.mp. 180 Advanced

60 valproate.mp. 690 Advanced

61 gabapentin.mp. 484 Advanced

62 levetiracetam.mp. 191 Advanced

63 lamotrigine.mp. 538 Advanced

64 felbamate.mp. 59 Advanced

65 tiagabine.mp. 126 Advanced

66 topiramate.mp. 417 Advanced

67 zonisamide.mp. 70 Advanced

68 pregabalin.mp. 163 Advanced


4

69 clobazam.mp. 160 Advanced

70 (carbamazepine or clonazepam or ethosuximide).mp. 1484 Advanced

71 (phenobarbital or phenytoin or primidone).mp. 1421 Advanced

72 (valproic acid or vigabatrin).mp. 937 Advanced

73 Diazepam/ 1784 Advanced

74 diazepam*.mp. 3349 Advanced

75 Lorazepam/ 634 Advanced

76 lorazepam*.mp. 1218 Advanced

77 benzodiazepine$.mp. 3546 Advanced

78 Benzodiazepines/ 1363 Advanced

79 or/47-78 12347 Advanced

Drug Interactions and related terms component

80 Drug Interactions/ 3824 Advanced

81 drug partial agonism/ 1 Advanced

82 drug antagonism/ 85 Advanced

83 drug inverse agonism/ 4 Advanced

84 drug synergism/ 1940 Advanced

85 (drug? adj2 interact*).tw. 1252 Advanced

86 (drug? adj2 (agonis* or antagonis* or synerg*)).tw. 383 Advanced

87 (drug? adj2 (toxicit* or safet*)).tw. 1138 Advanced

88 (ae or ag or ai or pk or pd or po or to).fs. 134549 Advanced

89 or/80-88 136866 Advanced

Combined results

90 46 and 79 and 89 17 Advanced

91 limit 90 to yr="2008 -Current" 3 Advanced


5

Results of database searches are subject to limitations of the database(s) searched. It is the responsibility of the requestor to determine the accuracy, validity and interpretation of the search results. While the staff of HealthSearch makes every effort to ensure that the information gathered is accurate and up-to-date, HealthSearch disclaims any warranties regarding the accuracy or completeness of the information or its fitness for a particular purpose. HealthSearch provides information from public sources both in electronic and print formats and does not guarantee its accuracy, completeness or reliability. The information provided is only for the use of the Client and no liability is accepted by HealthSearch to third parties.


1

Ovid MEDLINE(R) 1948 to December Week 4 2010

# Searches Results Search Type

HIV and related terms component

1 HIV Infections/ 111320 Advanced

2 exp HIV/ 67567 Advanced

3 Acquired Immunodeficiency Syndrome/ 68807 Advanced

4 human immunodeficiency virus*.tw. 58383 Advanced

5 AIDS Dementia Complex/ 2871 Advanced

6 (aids adj2 dementia adj2 complex).tw. 542 Advanced

7 human acquired immunodeficiency virus*.tw. 7 Advanced

8 (acquired adj2 immunodeficiency adj2 syndrome?).tw. 13563 Advanced


ARVs and related terms component

10 Anti-Retroviral Agents/ 3025 Advanced

11 Anti-HIV Agents/ 25133 Advanced

12 Delavirdine/ 184 Advanced

13 Didanosine/ 1821 Advanced

14 Lamivudine/ 4539 Advanced

15 Nevirapine/ 1840 Advanced

16 Stavudine/ 1445 Advanced

17 Zidovudine/ 8482 Advanced

18 azt.tw. 3677 Advanced

19 abacavir.mp. 1194 Advanced

20 amprenavir.mp. 686 Advanced

21 atazanavir.mp. 689 Advanced


2

22 darunavir.mp. 361 Advanced

23 efavirenz.mp. 1977 Advanced

24 efv.tw. 327 Advanced

25 emtricitabine.mp. 514 Advanced

26 enfuvirtide.tw. 486 Advanced

27 etravirine.mp. 238 Advanced

28 TMC125.tw. 47 Advanced

29 fosamprenavir.mp. 182 Advanced

30 Indinavir/ 1582 Advanced

31 Ritonavir/ 2347 Advanced

32 riton?vir.mp. 3428 Advanced

33 Nelfinavir/ 924 Advanced

34 raltegravir.mp. 316 Advanced

35 Saquinavir/ 1104 Advanced

36 tenofovir.mp. 1670 Advanced

37 tdf.tw. 754 Advanced

38 tipranavir.mp. 339 Advanced

39 d4T.tw. 822 Advanced

40 (Delavirdine or Didanosine or Lamivudine or Nevirapine).mp. 10095 Advanced

41 (Stavudine or Zidovudine or Indinavir or Nelfinavir).mp. 13941 Advanced

42 Saquinavir.mp. 1705 Advanced

43 arv.tw. 1022 Advanced

44 (antiretroviral* or anti retroviral*).mp. 30726 Advanced

45 or/10-44 58848 Advanced

46 9 or 45 226789 Advanced


3

AEDs and related terms component

47 Anticonvulsants/ 34892 Advanced

48 aed.tw. 2771 Advanced

49 (antiepileptic* or anticonvulsant*).mp. 44919 Advanced

50 carbamazepine/ 8422 Advanced

51 clonazepam/ 2086 Advanced

52 ethosuximide/ 802 Advanced

53 phenobarbital/ 16481 Advanced

54 phenytoin/ 11823 Advanced

55 primidone/ 1135 Advanced

56 valproic acid/ 8488 Advanced

57 vigabatrin/ 1317 Advanced

58 phenobarbitone.mp. 1958 Advanced

59 oxcarbazepine.mp. 1060 Advanced

60 valproate.mp. 6036 Advanced

61 gabapentin.mp. 3214 Advanced

62 levetiracetam.mp. 1158 Advanced

63 lamotrigine.mp. 3051 Advanced

64 felbamate.mp. 609 Advanced

65 tiagabine.mp. 729 Advanced

66 topiramate.mp. 2361 Advanced

67 zonisamide.mp. 730 Advanced

68 pregabalin.mp. 817 Advanced

69 clobazam.mp. 551 Advanced

70 (carbamazepine or clonazepam or ethosuximide).mp. 15394 Advanced


4

71 (phenobarbital or phenytoin or primidone).mp. 33798 Advanced

72 (valproic acid or vigabatrin).mp. 11258 Advanced

73 Diazepam/ 15915 Advanced

74 diazepam*.mp. 21541 Advanced

75 Lorazepam/ 2314 Advanced

76 lorazepam*.mp. 3269 Advanced

77 benzodiazepine$.mp. 32068 Advanced

78 Benzodiazepines/ 16011 Advanced

79 or/47-78 128234 Advanced

Drug interactions and related terms component

80 Drug Interactions/ 68863 Advanced

81 drug agonism/ 11 Advanced

82 drug partial agonism/ 83 Advanced

83 drug antagonism/ 4701 Advanced

84 drug inverse agonism/ 126 Advanced

85 drug synergism/ 51139 Advanced

86 (drug? adj2 interact*).tw. 18409 Advanced

87 (drug? adj2 (agonis* or antagonis* or synerg*)).tw. 2794 Advanced

88 (drug? adj2 safet*).tw. 2413 Advanced

89 (ae or ag or ai or pk or pd or po or to).fs. 3723000 Advanced

90 or/80-89 3745260 Advanced

Combined results

91 46 and 79 and 90 443 Advanced

Citations entry from 2008-2010

92 2008*.em. 708265 Advanced


5

93 2009*.em. 702879 Advanced

94 2010*.em. 718761 Advanced

95 or/92-94 2129905 Advanced

96 91 and 95 79 Advanced

97 limit 96 to (comment or editorial or news) 1 Advanced

98 96 not 97 78 Advanced Results of database searches are subject to limitations of the database(s) searched. It is the responsibility of the requestor to determine the accuracy, validity and interpretation of the search results. While the staff of HealthSearch makes every effort to ensure that the information gathered is accurate and up-to-date, HealthSearch disclaims any warranties regarding the accuracy or completeness of the information or its fitness for a particular purpose. HealthSearch provides information from public sources both in electronic and print formats and does not guarantee its accuracy, completeness or reliability. The information provided is only for the use of the Client and no liability is accepted by HealthSearch to third parties.

Web of Science: 2008-2011 Date Searched: January 14, 2011 Search Topic: Updated lit search, interaction between ARVs and AEDs

1

# 11 8 #10 AND #9 AND #6 Databases=SCI-EXPANDED Timespan=2008-2011

# 10 5,758 Topic=((drug? SAME interact*) OR (drug? SAME (agonis* or antagonis* or synerg*)) OR (drug? SAME safet*) OR (drug? SAME toxicit*)) Databases=SCI-EXPANDED Timespan=2008-2011

# 9 16,507 #8 OR #7 Databases=SCI-EXPANDED Timespan=2008-2011

# 8 10,525 Topic=(topiramate OR zonisamide OR pregabalin OR clobazam OR carbamazepine OR clonazepam OR ethosuximide OR phenobarbital OR phenytoin OR primidone OR valproic acid OR vigabatrin OR diazepam* OR lorazepam* OR Benzodiazepine*) Databases=SCI-EXPANDED Timespan=2008-2011

# 7 8,796 Topic=(antiepileptic* OR anticonvulsant* OR AED OR phenobarbitone OR oxcarbazepine OR valproate OR gabapentin OR levetiracetam OR lamotrigine OR felbamate OR tiagabine) Databases=SCI-EXPANDED Timespan=2008-2011

# 6 11,654 #5 AND #1 Databases=SCI-EXPANDED Timespan=2008-2011

# 5 15,500 #4 OR #3 OR #2 Databases=SCI-EXPANDED Timespan=2008-2011

# 4 1,936 Topic=(ARV OR EFV OR TMC125 OR NVP OR d4t OR TDF OR AZT) Databases=SCI-EXPANDED Timespan=2008-2011

# 3 13,898 Topic=(raltegravir OR tenofovir OR tipranavir OR Delavirdine OR Didanosine OR Lamivudine OR Nevirapine OR Stavudine OR Zidovudine OR Indinavir OR Nelfinavir OR Saquinavir OR antiretroviral* OR anti retroviral*) Databases=SCI-EXPANDED Timespan=2008-2011

# 2 2,692 Topic=(abacavir OR amprenavir OR atazanavir OR darunavir OR efavirenz OR emtricitabine OR enfuvirtide OR fosamprenavir OR riton?vir) Databases=SCI-EXPANDED Timespan=2008-2011

# 1 40,910 Topic=((human SAME immunodeficiency virus*) OR (aids SAME dementia SAME complex) OR HIV OR (acquired SAME immunodeficiency SAME syndrome*)) Databases=SCI-EXPANDED Timespan=2008-2011

Web of Science: 2008-2011 Date Searched: January 14, 2011 Search Topic: Updated lit search, interaction between ARVs and AEDs

2

Results of database searches are subject to limitations of the database(s) searched. It is the responsibility of the requestor to determine the accuracy, validity and interpretation of the search results. While the staff of HealthSearch makes every effort to ensure that the information gathered is accurate and up-to-date, HealthSearch disclaims any warranties regarding the accuracy or completeness of the information or its fitness for a particular purpose. HealthSearch provides information from public sources both in electronic and print formats and does not guarantee its accuracy, completeness or reliability. The information provided is only for the use of the Client and no liability is accepted by HealthSearch to third parties.

1. Van Der Westhuizen E, Van Der Merwe E. The safety and ... filehospitalists can avoid. Journal of...

Documents

Transcript of 1. Van Der Westhuizen E, Van Der Merwe E. The safety and ... filehospitalists can avoid. Journal of...